BLRX
BioLineRx Ltd.
$3.72
-$0.15(-3.88%)
10
Overall
--
Value
10
Tech
--
Quality
Market Cap
$14.47M
Volume
15.54K
52W Range
$2.30 - $26.80
Target Price
$26.00
Order:
Income Statement
| Metric | Trend | Chart | 2017 Dec | 2018 Dec | 2019 Dec | 2020 Dec | 2021 Dec | 2022 Dec | 2023 Dec | 2024 Dec |
|---|---|---|---|---|---|---|---|---|---|---|
| REVENUE | ||||||||||
| Total Revenue | -- | -- | -- | $-1.6M | -- | -- | $4.6M | $22.9M | ||
| Total Revenue | -- | -- | -- | $-1.6M | -- | -- | $4.8M | $28.9M | ||
| COST OF GOODS SOLD | ||||||||||
| Cost of Revenue | -- | -- | -- | -- | -- | -- | $3.7M | $9.3M | ||
| GROSS PROFIT | ||||||||||
| Gross Profit | -- | -- | -- | $-1.6M | -- | -- | $1.1M | $19.7M | ||
| OPERATING EXPENSES | ||||||||||
| Operating Expenses | $25.2M | $25.6M | $30.4M | $22.9M | $25.8M | $29.2M | $33.3M | $20.6M | ||
| Research & Development | $19.5M | $19.8M | $23.4M | $18.2M | $19.5M | $17.6M | $12.5M | $9.1M | ||
| Research Expense | $19.5M | $19.8M | $23.4M | $18.2M | $19.5M | $17.6M | $12.5M | $9.1M | ||
| Selling, General & Administrative | $5.7M | $5.8M | $7.0M | $4.8M | $6.3M | $11.5M | $31.6M | $29.9M | ||
| Selling & Marketing Expenses | $5.7M | $5.8M | $7.0M | $4.8M | $5.3M | $11.5M | $25.3M | $23.6M | ||
| General & Administrative Expenses | $-12.1M | $-11.6M | $-16.0M | $-11.7M | $1.0M | $-9.3M | $6.3M | $6.3M | ||
| Salaries & Wages | $-2.1M | $-2.5M | $-1.9M | $-1.4M | $-1.4M | $-1.7M | $21.4M | -- | ||
| Depreciation & Amortization | $-452.0K | $-424.0K | $-862.0K | $-864.0K | $-660.0K | $-615.0K | $934.0K | -- | ||
| Depreciation & Amortization | $-452.0K | $-424.0K | $-862.0K | $-864.0K | $-660.0K | $-615.0K | $934.0K | -- | ||
| Other Operating Expenses | $-440.0K | $-535.0K | $-417.0K | $-784.0K | $-108.0K | $-762.0K | $-10.8M | $-18.4M | ||
| OPERATING INCOME | ||||||||||
| Operating income | $-25.2M | $-25.6M | $-30.4M | $-24.6M | $-25.8M | $-31.3M | $-32.2M | $-963.0K | ||
| EBITDA | $-24.5M | $-25.8M | $-30.5M | $-27.6M | $-25.4M | $-22.5M | $-36.8M | $-102.0K | ||
| NON-OPERATING ITEMS | ||||||||||
| Interest Expense (Non-Operating) | -- | -- | $2.3M | $1.5M | $984.0K | $1.8M | $2.2M | $9.1M | ||
| Intinc | $1.2M | $719.0K | $777.0K | $236.0K | $559.0K | $694.0K | $2.1M | $1.9M | ||
| Net Non-Operating Interest Income/Expense | $1.2M | $719.0K | $777.0K | $236.0K | $559.0K | $1.1M | $-101.0K | $-7.2M | ||
| Other Income/Expense | $-38.8M | $-3.8M | $-20.3M | $-19.2M | $-50.4M | $5.3M | $-17.5M | -- | ||
| Other Special Charges | $38.8M | $3.8M | $20.3M | $19.2M | $50.4M | $18.2M | $235.0K | -- | ||
| SPECIAL ITEMS | ||||||||||
| Special Income Charges | $-21.0K | $-473.0K | -- | -- | -- | -- | $-6.7M | $-1.0M | ||
| Impairment of Capital Assets | -- | -- | -- | -- | -- | -- | $6.7M | $1.0M | ||
| PRE-TAX INCOME | ||||||||||
| EBIT | $-24.1M | $-25.4M | $-29.6M | $-28.6M | $-26.1M | $-23.2M | $-36.8M | $-102.0K | ||
| Pre-Tax Income | $-24.1M | $-25.4M | $-29.6M | $-24.3M | $-25.2M | $-25.0M | $-39.0M | $-9.2M | ||
| NET INCOME | ||||||||||
| Net Income | $-24.4M | $-23.0M | $-25.4M | $-30.0M | $-27.1M | $-25.0M | $-39.0M | $-9.2M | ||
| Net Income (Continuing Operations) | $-24.4M | $-23.0M | $-25.4M | $-30.0M | $-27.1M | $-25.0M | $-39.0M | $-9.2M | ||
| Net Income (Discontinued Operations) | $-24.4M | $-23.0M | $-25.4M | $-30.0M | $-27.1M | $-25.0M | $-39.0M | $-9.2M | ||
| Net Income (Common Stockholders) | $-24.4M | $-23.0M | $-25.4M | $-30.0M | $-27.1M | $-25.0M | $-39.0M | $-9.2M | ||
| Normalized Income | -- | -- | -- | -- | -- | -- | $-21.9M | $-8.1M | ||
| TOTALS | ||||||||||
| Total Expenses | $25.2M | $25.6M | $30.4M | $22.9M | $25.8M | $29.2M | $37.0M | $29.9M | ||
| SHARE & EPS DATA | ||||||||||
| Average Shares Outstanding | $10.0K | $12.1K | $244.0K | $421.4K | $1.1M | $51.6M | $963.4M | $1.2B | ||
| Average Shares Outstanding (Diluted) | $10.0K | $12.1K | $244.0K | $421.4K | $1.1M | $55.4M | $963.4M | $1.2B | ||
| Shares Outstanding | $175.1K | $191.6K | $4.3M | $8.7M | $17.9M | $923.0M | $3.7M | $1.1B | ||
| Basic EPS | $-2.4K | $-1.9K | $-102 | $-72 | $-24 | $-0.45 | $-0.06 | $-0.01 | ||
| Basic EPS (Continuing Operations) | $-2.4K | $-1.9K | $-102 | $-72 | $-24 | $-0.45 | $-0.06 | $-0.01 | ||
| Diluted EPS | -- | -- | $-102 | $-72 | $-24 | $-0.45 | $-0.06 | $-0.01 | ||
| Diluted EPS (Continuing Operations) | -- | -- | $-102 | $-72 | $-24 | $-0.45 | $-0.06 | $-0.01 | ||
| OTHER METRICS | ||||||||||
| Acquisition Expense | -- | -- | -- | -- | -- | $2.2M | -- | -- | ||
| Allowances For Construction | -- | -- | -- | -- | $1.0M | -- | -- | -- | ||
| Commission Expenses | $-21.0K | $-21.0K | $-24.0K | $-22.0K | $-22.0K | $-26.0K | -- | -- | ||
| Development Expense | -- | -- | -- | $1.6M | -- | -- | -- | -- | ||
| Fees | -- | -- | -- | $-1.6M | -- | -- | -- | -- | ||
| Insurance And Claims | $-210.0K | $-221.0K | $-298.0K | $-603.0K | $1.0M | $-1.0M | $939.0K | -- | ||
| Marketing Expense | -- | $473.0K | -- | -- | -- | -- | -- | -- | ||
| Net Income From Other Gains Losses | $-260.0K | $2.4M | $4.2M | $-5.7M | $-1.8M | $5.7M | -- | -- | ||
| Non Recurring Operation Expense | $21.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Other Costof Revenue | -- | -- | -- | -- | -- | -- | $3.7M | $9.3M | ||
| Other Gand A | $-12.1M | $-11.6M | $-16.0M | $-11.7M | $1.0M | $-9.3M | $6.3M | $6.3M | ||
| Other Impairment Of Capital Assets | $21.0K | -- | -- | -- | -- | -- | -- | -- | ||
| Selling Expense | $5.7M | $5.8M | $4.7M | $4.8M | $5.3M | $11.5M | -- | -- | ||
| Write Down | -- | $473.0K | -- | -- | -- | -- | -- | -- | ||
Financial data is updated quarterly and may not reflect the most recent earnings.
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | BLRX | $3.72 | -3.9% | 15.54K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |